vs
碧迪（BDX）与Exelon（EXC）财务数据对比。点击上方公司名可切换其他公司
Exelon的季度营收约是碧迪的1.0倍（$5.4B vs $5.3B），碧迪同比增速更快（-0.4% vs -19.4%），过去两年碧迪的营收复合增速更高（2.0% vs 0.5%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Exelon是总部位于美国芝加哥、在宾夕法尼亚州注册的公用事业企业，按营收计算为美国最大的电力母公司，同时是美国规模最大的受监管电力公用事业公司，服务约1000万用户，位列《财富》世界500强第187位。
BDX vs EXC — 直观对比
营收规模更大
EXC
是对方的1.0倍
$5.3B
营收增速更快
BDX
高出19.0%
-19.4%
两年增速更快
BDX
近两年复合增速
0.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $5.4B |
| 净利润 | $382.0M | — |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 21.9% |
| 净利率 | 7.3% | — |
| 营收同比 | -0.4% | -19.4% |
| 净利润同比 | 24.0% | — |
| 每股收益（稀释后） | $1.34 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXEXC
| Q1 26 | — | $5.4B | ||
| Q4 25 | $5.3B | $5.4B | ||
| Q3 25 | $5.9B | $6.7B | ||
| Q2 25 | $5.5B | $5.4B | ||
| Q1 25 | $5.3B | $6.7B | ||
| Q4 24 | $5.2B | $5.5B | ||
| Q3 24 | $5.4B | $6.2B | ||
| Q2 24 | $5.0B | $5.4B |
净利润BDXEXC
| Q1 26 | — | — | ||
| Q4 25 | $382.0M | $594.0M | ||
| Q3 25 | $493.0M | $875.0M | ||
| Q2 25 | $574.0M | $391.0M | ||
| Q1 25 | $308.0M | $908.0M | ||
| Q4 24 | $303.0M | $647.0M | ||
| Q3 24 | $400.0M | $707.0M | ||
| Q2 24 | $487.0M | $448.0M |
毛利率BDXEXC
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — |
营业利润率BDXEXC
| Q1 26 | — | 21.9% | ||
| Q4 25 | 10.5% | 21.9% | ||
| Q3 25 | 11.8% | 22.4% | ||
| Q2 25 | 16.0% | 17.1% | ||
| Q1 25 | 10.4% | 22.9% | ||
| Q4 24 | 8.8% | 20.0% | ||
| Q3 24 | 11.4% | 19.4% | ||
| Q2 24 | 12.1% | 17.0% |
净利率BDXEXC
| Q1 26 | — | — | ||
| Q4 25 | 7.3% | 11.0% | ||
| Q3 25 | 8.4% | 13.0% | ||
| Q2 25 | 10.4% | 7.2% | ||
| Q1 25 | 5.8% | 13.5% | ||
| Q4 24 | 5.9% | 11.8% | ||
| Q3 24 | 7.4% | 11.5% | ||
| Q2 24 | 9.8% | 8.4% |
每股收益（稀释后）BDXEXC
| Q1 26 | — | — | ||
| Q4 25 | $1.34 | — | ||
| Q3 25 | $1.71 | $0.86 | ||
| Q2 25 | $2.00 | $0.39 | ||
| Q1 25 | $1.07 | $0.90 | ||
| Q4 24 | $1.04 | — | ||
| Q3 24 | $1.37 | $0.70 | ||
| Q2 24 | $1.68 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $626.0M |
| 总债务越低越好 | — | $49.4B |
| 股东权益账面价值 | $25.3B | $28.8B |
| 总资产 | $54.8B | $116.6B |
| 负债/权益比越低杠杆越低 | — | 1.72× |
8季度趋势，按日历期对齐
现金及短期投资BDXEXC
| Q1 26 | — | $626.0M | ||
| Q4 25 | $740.0M | $626.0M | ||
| Q3 25 | $641.0M | $1.5B | ||
| Q2 25 | $735.0M | $724.0M | ||
| Q1 25 | $667.0M | $1.0B | ||
| Q4 24 | $711.0M | $357.0M | ||
| Q3 24 | $1.7B | $616.0M | ||
| Q2 24 | $4.5B | $934.0M |
总债务BDXEXC
| Q1 26 | — | $49.4B | ||
| Q4 25 | — | $49.4B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $44.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BDXEXC
| Q1 26 | — | $28.8B | ||
| Q4 25 | $25.3B | $28.8B | ||
| Q3 25 | $25.4B | $28.1B | ||
| Q2 25 | $25.5B | $27.6B | ||
| Q1 25 | $25.2B | $27.6B | ||
| Q4 24 | $25.2B | $26.9B | ||
| Q3 24 | $25.9B | $26.6B | ||
| Q2 24 | $25.9B | $26.2B |
总资产BDXEXC
| Q1 26 | — | $116.6B | ||
| Q4 25 | $54.8B | $116.6B | ||
| Q3 25 | $55.3B | $113.5B | ||
| Q2 25 | $54.9B | $111.1B | ||
| Q1 25 | $54.5B | $109.5B | ||
| Q4 24 | $54.7B | $107.8B | ||
| Q3 24 | $57.3B | $106.1B | ||
| Q2 24 | $55.6B | $105.1B |
负债/权益比BDXEXC
| Q1 26 | — | 1.72× | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.66× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | — |
| 自由现金流经营现金流 - 资本支出 | $549.0M | — |
| 自由现金流率自由现金流/营收 | 10.5% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $2.6B | — |
8季度趋势，按日历期对齐
经营现金流BDXEXC
| Q1 26 | — | — | ||
| Q4 25 | $657.0M | $1.2B | ||
| Q3 25 | $1.4B | $2.3B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $164.0M | $1.2B | ||
| Q4 24 | $693.0M | $1.4B | ||
| Q3 24 | $1.2B | $1.7B | ||
| Q2 24 | $1.3B | $1.5B |
自由现金流BDXEXC
| Q1 26 | — | — | ||
| Q4 25 | $549.0M | $-1.2B | ||
| Q3 25 | $1.0B | $163.0M | ||
| Q2 25 | $1.0B | $-502.0M | ||
| Q1 25 | $35.0M | $-746.0M | ||
| Q4 24 | $588.0M | $-510.0M | ||
| Q3 24 | $882.0M | $-6.0M | ||
| Q2 24 | $1.1B | $-237.0M |
自由现金流率BDXEXC
| Q1 26 | — | — | ||
| Q4 25 | 10.5% | -22.0% | ||
| Q3 25 | 17.0% | 2.4% | ||
| Q2 25 | 19.0% | -9.3% | ||
| Q1 25 | 0.7% | -11.1% | ||
| Q4 24 | 11.4% | -9.3% | ||
| Q3 24 | 16.2% | -0.1% | ||
| Q2 24 | 22.4% | -4.4% |
资本支出强度BDXEXC
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 45.0% | ||
| Q3 25 | 6.0% | 31.9% | ||
| Q2 25 | 3.2% | 37.1% | ||
| Q1 25 | 2.4% | 29.0% | ||
| Q4 24 | 2.0% | 35.4% | ||
| Q3 24 | 5.4% | 27.5% | ||
| Q2 24 | 3.6% | 31.7% |
现金转化率BDXEXC
| Q1 26 | — | — | ||
| Q4 25 | 1.72× | 2.09× | ||
| Q3 25 | 2.75× | 2.63× | ||
| Q2 25 | 2.12× | 3.86× | ||
| Q1 25 | 0.53× | 1.32× | ||
| Q4 24 | 2.29× | 2.20× | ||
| Q3 24 | 2.94× | 2.39× | ||
| Q2 24 | 2.66× | 3.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
EXC
暂无分部数据
